These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Fikrig E; Telford SR; Barthold SW; Kantor FS; Spielman A; Flavell RA Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5418-21. PubMed ID: 1608951 [TBL] [Abstract][Full Text] [Related]
3. Vaccination against Lyme disease caused by diverse Borrelia burgdorferi. Fikrig E; Telford SR; Wallich R; Chen M; Lobet Y; Matuschka FR; Kimsey RB; Kantor FS; Barthold SW; Spielman A; Flavell RA J Exp Med; 1995 Jan; 181(1):215-21. PubMed ID: 7807004 [TBL] [Abstract][Full Text] [Related]
4. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of human Lyme disease vaccine formulations in a mouse model. Telford SR; Kantor FS; Lobet Y; Barthold SW; Spielman A; Flavell RA; Fikrig E J Infect Dis; 1995 May; 171(5):1368-70. PubMed ID: 7751719 [TBL] [Abstract][Full Text] [Related]
6. Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC. Zhong W; Gern L; Stehle T; Museteanu C; Kramer M; Wallich R; Simon MM Eur J Immunol; 1999 Mar; 29(3):946-57. PubMed ID: 10092099 [TBL] [Abstract][Full Text] [Related]
7. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Probert WS; LeFebvre RB Infect Immun; 1994 May; 62(5):1920-6. PubMed ID: 8168958 [TBL] [Abstract][Full Text] [Related]
8. Evasion of protective immunity by Borrelia burgdorferi by truncation of outer surface protein B. Fikrig E; Tao H; Kantor FS; Barthold SW; Flavell RA Proc Natl Acad Sci U S A; 1993 May; 90(9):4092-6. PubMed ID: 7683420 [TBL] [Abstract][Full Text] [Related]
9. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites. Gern L; Rais O; Capiau C; Hauser P; Lobet Y; Simoen E; Voet P; PĂȘtre J Immunol Lett; 1994 Mar; 39(3):249-58. PubMed ID: 8034340 [TBL] [Abstract][Full Text] [Related]
10. Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype. Schaible UE; Wallich R; Kramer MD; Gern L; Anderson JF; Museteanu C; Simon MM Vaccine; 1993; 11(10):1049-54. PubMed ID: 8212826 [TBL] [Abstract][Full Text] [Related]
11. Resistance to tick-borne spirochete challenge induced by Borrelia burgdorferi strains that differ in expression of outer surface proteins. Kurtti TJ; Munderloh UG; Hughes CA; Engstrom SM; Johnson RC Infect Immun; 1996 Oct; 64(10):4148-53. PubMed ID: 8926082 [TBL] [Abstract][Full Text] [Related]
12. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21. Coughlin RT; Fish D; Mather TN; Ma J; Pavia C; Bulger P J Infect Dis; 1995 Apr; 171(4):1049-52. PubMed ID: 7706788 [TBL] [Abstract][Full Text] [Related]
13. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Golde WT; Piesman J; Dolan MC; Kramer M; Hauser P; Lobet Y; Capiau C; Desmons P; Voet P; Dearwester D; Frantz JC Infect Immun; 1997 Mar; 65(3):882-9. PubMed ID: 9038292 [TBL] [Abstract][Full Text] [Related]
14. Vaccination as a modality to prevent Lyme disease. A status report. Wormser GP Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796 [TBL] [Abstract][Full Text] [Related]
15. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Scheckelhoff MR; Telford SR; Hu LT Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863 [TBL] [Abstract][Full Text] [Related]
16. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis. Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431 [TBL] [Abstract][Full Text] [Related]
17. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. de Silva AM; Telford SR; Brunet LR; Barthold SW; Fikrig E J Exp Med; 1996 Jan; 183(1):271-5. PubMed ID: 8551231 [TBL] [Abstract][Full Text] [Related]
18. Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice. Bockenstedt LK; Fikrig E; Barthold SW; Kantor FS; Flavell RA J Immunol; 1993 Jul; 151(2):900-6. PubMed ID: 8335917 [TBL] [Abstract][Full Text] [Related]
19. Selection of variant Borrelia burgdorferi isolates from mice immunized with outer surface protein A or B. Fikrig E; Tao H; Barthold SW; Flavell RA Infect Immun; 1995 May; 63(5):1658-62. PubMed ID: 7729870 [TBL] [Abstract][Full Text] [Related]
20. Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. Probert WS; Crawford M; Cadiz RB; LeFebvre RB J Infect Dis; 1997 Feb; 175(2):400-5. PubMed ID: 9203661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]